ClinicalTrials.gg
RecruitingNCT05585190Updated May 4, 2026

Stand up for Your Health With a Sit-stand Desk

An interventional study of Control and Sit-Stand Desk at Work in Pre Diabetes, Obesity and Metabolic Syndrome, sponsored by Medical College of Wisconsin. Recruiting at 1 site in United States. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2026-05-04.

Sponsored by Medical College of Wisconsin · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Started Feb 2023; still recruiting 3 years 9 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
198
Allocation
Randomized
Ages
18 Years to 79 Years
Sex
All
01

Study summary

More than 84 million - or 1 out of every 3 U.S. adults - have prediabetes, a condition that if not treated often leads to type 2 diabetes within five years. Average medical expenditures among diabetics are about 2.3 times higher than expenditures for people without diabetes. Physical inactivity and elevated body mass index (BMI) are major risk factors for the disease. Sedentary behavior is becoming increasingly prevalent with the growth of a 'work from home' culture, most recently driven by the COVID-19 pandemic. Cross-sectional epidemiologic data report significant associations between high amounts of sedentary (sitting) time and prevalent cardiovascular disease and diabetes. In our pilot study of 15 subjects with sedentary office jobs, 6 months of sit-stand desk use resulted in a 23% improvement in insulin resistance, most substantial in those who decreased daily sitting by over 90 minutes/day. Additional improvements in vascular endothelial function and triglyceride levels were seen without any change in exercise activity, step counts, or body weight. These findings not only corroborate epidemiologic findings on this topic but suggest causality and warrant a randomized control trial.

The investigators hypothesize that adult subjects at-risk for diabetes will improve insulin sensitivity, metabolic and vascular (endothelial) health with a sit-stand desk intervention at work (whether in the office or at home), in the context of a randomized, controlled trial. The investigators will randomize 198 sedentary office workers with a BMI≥25 at risk for type 2 diabetes mellitus in a 1:1:1 ratio of three groups: (a) sit-stand desk intervention targeting 2 hours standing per day; (b) sit-stand desk intervention targeting 3 hours standing per day; or (c) control arm over 6 months. The block randomization design will allow for important dose-response analyses.

The investigators will objectively quantify standing time, sedentary time, sedentary bouts, daily steps, and exercise activity times using a compact and re-usable accelerometer that adheres to the subject's thigh. This will provide objective assessments of activity levels and sedentary times for 7 full days each at baseline, 3 and 6 months. The device is equipped with an inclinometer to classify posture (sitting verses standing).

02

Conditions studied

  • Pre Diabetes
  • Obesity
  • Metabolic Syndrome
  • Sedentary Behavior

Keywords

  • Pre Diabetes
  • Obesity
  • Metabolic Syndrome
  • Cardiovascular
  • Sit-stand desk
  • Physical Activity
  • Overweight
  • Sedentary
  • Standing desk
  • Insulin resistance
03

In context

Glucose Intolerance

793 studies on the registry are indexed under Glucose Intolerance; 115 are open to participants now.

This study's planned enrollment of 198 is above the median of 56 across 661 interventional studies indexed under Glucose Intolerance.

Browse Glucose Intolerance studies →

Lead sponsor

Medical College of Wisconsin is the lead sponsor of 548 studies on the registry; 122 are open to participants now.

Of its 75 completed or terminated interventional studies of FDA-regulated products, 57 (76%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Overweight or obese ( of 25 kg/m2 or higher)
  2. Employees with "sedentary" jobs, defined as spending at least 75% of their (8 hours or more) workday sitting at a desk (at home or in an office)
  3. Defined as "at-risk" for diabetes, defined as either:

    1. Prediabetes ( of 5.7% to 6.4%) or a fasting glucose of 100 to 125 mg/dL
    2. Having one or more additional risk factors: (beyond BMI>25)

      • Age 45 years or older
      • Family history of diabetes mellitus in a first-degree relative
      • Physical inactivity (no structured exercise activity)
      • History of gestational diabetes, hypertension, or dyslipidemia
      • African American, Alaska Native, American Indian, Asian American, Hispanic/Latino, Native Hawaiian, or Pacific Islander ethnicity

Exclusion criteria

Exclusion Criteria:

  1. Established cardiovascular disease (myocardial infarction, coronary stent, coronary artery bypass grafting, cardiac transplant, or angina)
  2. Established congestive heart failure or cardiomyopathy
  3. Established peripheral vascular disease
  4. Established diabetes ( ≥ 6.5% or on diabetes medications or insulin)
  5. Chronic musculoskeletal disorders involving the lower extremities, such as arthritis of the knees or hips, or regular use of ambulatory assist devices such as a walker or cane
  6. Neuropathy of any etiology
  7. Positional syncope or history of orthostasis
  8. Less than 4 days/week at any single office (or work-from-home) location.
  9. Current use of a standing desk for work
  10. Tobacco use within the previous 12 months
  11. Current illicit drug use or excessive alcohol use (defined as more than 14 drinks/week for women, more than 28 drinks/week for men)
  12. use ≥21 days/year
  13. Fasting triglyceride level ≥ 500 mg/dL
  14. Thyroid disease
  15. Uncontrolled or untreated hypertension(>150/90 mm Hg)
  16. Pregnant or lactating (or plans to become pregnant in the next 6 months)
  17. LDL cholesterol ≥ 190mg/dL
  18. Currently enrolled or plans to diet or join a weight loss program over the next 6 months.
  19. Non-English speaker
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
198 participants (estimated)

Study arms

  • Other
    Control

    Subjects will not receive a sit/stand desk for the duration of the study and will be asked to follow their normal work day routine.

    Other: Control

  • Active comparator
    2-Hour Group

    Sit-stand desk intervention group, subjects are asked to maintain the desk in the standing position at LEAST 2 hours each work day.

    Other: Sit-Stand Desk at Work

  • Active comparator
    3-Hour Group

    Sit-stand desk intervention group, subjects are asked to maintain the desk in the standing position at LEAST 3 hours each work day.

    Other: Sit-Stand Desk at Work

Interventions

  • OtherControl

    No intervention.

  • OtherSit-Stand Desk at Work

    Subjects will receive a sit-stand desk at their work location.

06

What researchers measure

Primary outcomes

  1. Insulin sensitivity (HOMA-IR)

    Determine if use of a sit-stand desk improves insulin sensitivity and ascertain if there is a dose-response relationship with changes in sedentary time.

    Time frame: change from baseline to 6 months

Secondary outcomes

  1. HbA1c

    Determine if use of a sit-stand desk improves HbA1c.

    Time frame: change from baseline to 6 months

  2. fasting glucose

    Determine if use of a sit-stand desk improves fasting glucose.

    Time frame: change from baseline to 6 months

  3. fasting insulin level

    Determine if use of a sit-stand desk improves (reduces) fasting insulin levels.

    Time frame: change from baseline to 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Bodker A, Visotcky A, Gutterman D, Widlansky ME, Kulinski J. The impact of standing desks on cardiometabolic and vascular health. Vasc Med. 2021 Aug;26(4):374-382. doi: 10.1177/1358863X211001934. Epub 2021 Apr 5. PubMed 33813968 ↗
  • Hammad M, Shankar S, Gao Y, Kulinski J. Stand up for your health: Rationale and design for a randomized controlled trial. Contemp Clin Trials. 2026 Feb;161:108216. doi: 10.1016/j.cct.2026.108216. Epub 2026 Jan 6. PubMed 41506470 ↗

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Informed consent form

Time frame: Within 1 year of completion of all studies procedures

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05585190
Responsible party
Jacquelyn Kulinski (Principal Investigator, Associate Professor, Medical College of Wisconsin) — Principal investigator
First posted
Oct 18, 2022
Start date
Feb 6, 2023
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
May 4, 2026

Study contacts

Jacquelyn Kulinski, MD
Contact
jakulinski@mcw.edu
414-955-6896
Ryan Kacala
Contact
rkacala@mcw.edu
414-955-6885

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion